E-mail Address
[email protected]

Aaron Figg, Director
"We strive to support our customers in developing more and better biopharmaceuticals to treat patients. By continually innovating to create unique and unrivalled technologies, we bring practical solutions to the problems of the drug discovery and development process"

Optimising workflows

We provide solutions for customers working across cell line development:

Novel Biotherapeutics

Isolate, screen and characterise attributes for clones producing novel recombinant proteins e.g. monoclonal antibodies or therapeutic proteins for rare diseases

Read More >

Biosimilars and Biobetters

Generate stable cell lines to create equivalents (Biosimilars) or improved versions (Biobetters) of existing blockbuster therapeutic antibodies for which the patent has, or will shortly, expire

Read More >

Gene Therapy & CAR-T

Develop new, stable, producer cell lines manufacturing viruses to subsequently infect target cells of patients

Read More >

Gene Editing & Cell Engineering

Optimise your drug discovery process using targeted gene editing to create stable cell lines as cellular reagents, for use in target validation, functional genomics and disease modelling

Read More >

VIEW OUR WEBINAR

"How a Top-5 Pharma Doubled the Speed of Cell Line Development"

Latest News

Proof of clonality and its importance in stable cell line development

What is clonality and why is it important Clonality is a crucial step in stable cell line development (CLD) for biotherapeutic workflows and one closely monitored by the medicines’ regulators.

Continuous innovation of host cell lines for cell line development

Insights from the Oxford Global Cell Series UK Conference on the ongoing innovation driving new requirements for cell lines Author: Ian Taylor, Chief Commercial Officer, Solentim At last week’s Oxford

Eliminating enrichment steps in cell line development – reduce cell screening from 5000 to 200 clones per project

Coffee Morning Chat with Ferenc Boldog (ATUM) and Ian Taylor (Solentim): An expert discussion on the evolution of cell line development to negate the need for enrichment In the time

Mark Stockdale joins Solentim in new “Amalgamator of Business and Biology” position

Bournemouth, UK, 8th October 2019: Solentim, the global leader in cell line development instrumentation, is delighted to announce that Mark Stockdale is starting at Solentim in a brand-new role as

Dr Mark Truesdale joins Solentim as new Chief Marketing Officer

Dr Mark Truesdale Solentim, the global leader in cell line development (CLD) instrumentation, is delighted to announce that Dr Mark Truesdale will join the Company as

A bright future ahead for cell line development in China

Dr Andy Tsun, Co-Founder & VP of Discovery Biology at Biotheus Inc China has experienced rapid economic growth over the last ten years. Thanks to economic

GSK presentation on the VIPS system at the forthcoming 8th Annual Cell Culture & Bioprocessing Congress in London re-enforces Solentim’s long-term vision and leadership in cell line development

Solentim is excited to be attending and exhibiting at Oxford Global’s 8th Annual Cell Culture & Bioprocessing Congress, taking place 29-30 October in London. GSK, a valued customer of Solentim,

Solentim to present with Celonic at Biotech Week Boston: new-look VIPS will also premiere at the trade booth

Solentim, a global leader in cell line development instrumentation, is pleased to announce it will be attending and exhibiting at Biotech Week Boston, taking place 9-12 September. Camille Evenou, Scientist

Solentim in the Press: “Increasing HD-BIOP3 Seeding Efficiencies using the VIPS” GEN Tutorial

Read this new Bioprocessing Tutorial in the latest edition of Genetic Engineering News (GEN). In this educational piece, scientists at Solentim demonstrate the ways in which they have systematically been

Solentim reports continued strong growth in 2019

NEWS - Bournemouth, UK – 8th August 2019: Solentim, the innovator and World leader in Cell Line Development instrumentation, is pleased to announce that it achieved very strong revenue growth and